allergy-clinical-immunology-2017-posters-abstracts

8 / 25

Page 60
Notes:
conferenceseries.com
Volume 8, Issue 3(Suppl) J Allergy Ther, an open access journal
ISSN: 2155-6121 Allergy-Clinical Immunology 2017
September 07-08, 2017
September 07-08, 2017 | Edinburgh, Scotland
ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY
11th International Conference on
Allergic onset against hyaluronidase used to treat overcorrection of hyaluronic acid filler injection
Tatiana Chioro and Adilson da Costa
Hospital do Servidor Público Estadual – IAMSPE, Brazil
Hyaluronic acid (HA) is biocompatible, easy-to-use, and reversible filler which is broadly-based filler in cosmetic medicine.
More and more, non-expert physicians and non-physicians practitioners have been performing fillers in a large number
of patients, which notices a high risk of unwanted outcomes, either in efficacy and safety fields. Unwanted results can mean
overcorrection and asymmetries, as well as adverse events against these injectable fillers. Although HA-based fillers are
defined as temporary materials, they can last up to 12 months or longer. Hyaluronidase is an endogenous enzyme that has
a potent activity, which lets it to hydrolyze tissue HA, which is the key element of connective tissue. Given that, commercial
hyaluronidase, when injected in areas wherein HA-based filler was placed, destroys HA and gives the possibility to adjust
overcorrection and asymmetries. Although hyaluronidase has been used worldwide, only a few allergic reactions have been
reported. Most of the described patients showed allergic reactions after peribulbar anesthesia for eye surgery despite the large
use of HA fillers in aesthetic medicine. A 29-year-old Brazilian female patient was subjected to a 0.01 mL hyaluronidase
injection (Pineda Laboratories, Sao Paulo, Brazil) in order to treat a malar hypercorrection as result of filling with HA. After
about 10 minutes, she evolved with discrete erythema and edema at the injection site. A vial of 1 mL intramuscular injection
of 5 mg/mL betamethasone dipropionate+2 mg/mL betamethasone disodium phosphate 2 mg/mL (BetaTrinta, Eurofarma,
Sao Paulo/SP, Brazil) was immediately administered. After 1 hour, however, the patient presented an intense edema in her
left hemiface, which suggested angioedema onset; this adverse event was immediately treated by injecting 4 mL of 500 mg
hydrocortisone sodium succinate which helped her to clinically overcome such condition. Though, the patient was discharged
to home with 40 mg/day/3 days of micronized prednisolone. A complete clinical improvement was observed in five days.
In summary, side effects against hyaluronidase injections are rare in accordance with already published scientific literature;
however, it is extremely important for professionals of cosmetic medicine to be an emergency conduct at their office.
Biography
Tatiana Chioro is a Brazilian Physician with experience in Cosmetic Dermatology. She is Member of Brazilian Society of Dermatology, American Academy of
Dermatology and European Academy of Dermatology and Venereology. She is also an MSc candidate at Hospital do Servidor Público Estadual – IAMSPE, Brazil.
Tatiana Chioro et al., J Allergy Ther 2017, 8:3(Suppl)
DOI: 10.4172/2155-6121-C1-006